As Brazilian federal health regulator Anvisa issued emergency approval for 6 million doses of the Chinese-made CoronaVac and 2 million of AstraZeneca’s vaccine, its board members detailed exactly what they analyzed in the data provided by each laboratory. And while the regulatory approval is a landmark in Brazil’s fight against the pandemic, there remains a long way to go before both vaccines get unrestricted authorization for use and distribution.
Gustavo Mendes, in charge of Anvisa’s medication safety department, recommended that regulators “keep a very close eye on the uncertainties [around each vaccine] and constantly reassess their development.” He continued: “If we don’t monitor it closely...
It wasn’t since Argentina last won the World Cup in 2022 that the streets of…
President Luiz Inácio Lula da Silva issued a provisional decree laying the foundations for Eco…
Finance Minister Fernando Haddad on Wednesday delivered to House Speaker Arthur Lira a bill with…
Brazil's IPCA-15 mid-month inflation measurement posted a 0.21 percent increase in April, following the 0.36…
It is not about denying the environmental problems and challenges Brazil faces — that are…
Shareholders of Brazil’s oil giant Petrobras approved in a Thursday general meeting the payment of…